Basic and clinical studies on tazobactam/piperacillin in the surgical field

Jiro Yura, Nagao Shinagawa, Shu Ishikawa, Akira Mizuno, Keiji Mashita, Hiroshi Ishihara, Masazumi Hisada, Tomokatsu Fukuhara, Yoshimasa Tachi, Nobuatsu Tsuruga, Akitoshi Ito, Keiichi Hori, Hideya Okada, Takashi Miyake, Tatsuya Suzuki, Akihiko Iwai, Hiroshi Mizuno, Tetsushi Hayakawa, Yuji Okada, Shouji KimuraIchiya Suzuki, Akishige Nakamura, Katsuhiko Tanabe, Yota Yamagishi

Research output: Contribution to journalArticlepeer-review


We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), an injectable antibiotic which is a combination of piperacillin (PIPC) and tazobactam (TAZ), a newly developed β-lactamase inhibitor, in the field of surgery. The following results were obtained. 1) Delivery into bile: Concentrations of PIPC, TAZ and desethyl-piperacillin (DEt-PIPC) in bile were measured in a postoperative patient with gall stone disease after intravenous drip infusion of TAZ/PIPC at 2.5 g. The peak levels in bile were 256 μg/ml, 9.98 μg/ml and 1340 μg/ml, respectively. 2) Clinical evaluation: 24 patients with surgical infections were treated with TAZ/PIPC. Clinical efficacy was excellent in 10 cases, good in 10, fair in 2 and poor in 2, the overall efficacy rate being 83.3%. Bacteriological response was observed as eradicated in 12 cases, partially eradicated in 1, replaced in 1 and unchanged in 4, resulting in a 72.2% eradication rate. No adverse reactions were observed, and abnormal changes in laboratory findings appeared in three patients.

Original languageEnglish
Pages (from-to)581-589
Number of pages9
Publication statusPublished - 1994
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Basic and clinical studies on tazobactam/piperacillin in the surgical field'. Together they form a unique fingerprint.

Cite this